Chemomab Therapeutics Ltd reports results for the quarter ended in March - Earnings Summary

Chemomab Therapeutics

12/05/2022 13:01

* Chemomab Therapeutics Ltd  CMMB.OQ  reported a quarterly
adjusted loss of 44 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 24 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Chemomab Therapeutics Ltd's reported EPS for the quarter
was a
loss of 44 cents​.
    * The mean earnings estimate of analysts had fallen by
about 69%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Chemomab Therapeutics Ltd shares had fallen by 45.7% this
quarter and lost 62.2% so far this year.
    * The company reported a quarterly loss of $5.1 million.
    * Wall Street's median 12-month price target for Chemomab
Therapeutics Ltd is $25.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 12:01 p.m.  ​All
figures in US dollars unless otherwise stated